TrialLeukemia2026

Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.

Hagop Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.